Metronidazole dose
| Patient | Dose |
|---|---|
| Child | 35-50 mg/kg/24 hr PO divided Q8 hr x 10 days; max 750 mg/dose |
| Adult | 500-750 mg PO Q8 hr x 10 days |
| Patient | Dose |
|---|---|
| Neonate (loading) | 15 mg/kg x 1, then maintenance by postmenstrual age (PMA): |
| PMA 24-25 wk | 7.5 mg/kg Q24 hr |
| PMA 26-27 wk | 10 mg/kg Q24 hr |
| PMA 28-33 wk | 7.5 mg/kg Q12 hr |
| PMA 34-40 wk | 7.5 mg/kg Q8 hr |
| PMA >40 wk | 7.5 mg/kg Q6 hr |
| Infant/Child/Adolescent PO | 30-50 mg/kg/24 hr divided Q8 hr; max 2250 mg/24 hr |
| Infant/Child/Adolescent IV | 22.5-40 mg/kg/24 hr divided Q6-8 hr; max 4 g/24 hr |
| Adult PO/IV | 30 mg/kg/24 hr divided Q6-8 hr; max 4 g/24 hr. (Give 15 mg/kg IV loading dose over 1 hr, 6 hr before maintenance for IV route) |
| Route | Dose |
|---|---|
| PO (child >45 kg, adolescent, adult) | 500 mg BID x 7 days |
| Vaginal gel 0.75% | ~37.5 mg (1 applicatorful) QHS x 5 days |
| Vaginal gel 1.3% (≥12 yr) | ~65 mg (1 applicatorful) at bedtime x 1 |
Note: Single-dose oral regimen is no longer recommended for BV due to poor efficacy.
| Patient | Dose |
|---|---|
| Child | 15-30 mg/kg/24 hr PO divided TID x 5-7 days; max 750 mg/24 hr |
| Adult | 250 mg PO TID x 5 days |
| Patient | Dose |
|---|---|
| Child <45 kg | 45 mg/kg/24 hr PO divided TID x 7 days; max 2000 mg/24 hr |
| Child ≥45 kg, adolescent, adult | 2 g PO x 1 (single dose), OR 500 mg PO BID x 7 days |
Multi-dose regimen (500 mg BID x 7 days) shows increased efficacy in women over the single 2 g dose.
| Patient | Dose |
|---|---|
| Child | 30 mg/kg/24 hr divided Q6 hr PO/IV x 10-14 days; max 2000 mg/24 hr |
| Child - severe fulminant (+ oral/rectal vancomycin) | 30 mg/kg/24 hr divided Q8 hr IV x 10 days; max 500 mg/dose |
| Adult | 500 mg TID PO/IV x 10-14 days |
| Adult - severe fulminant (+ oral/rectal vancomycin) | 500 mg IV Q8 hr |
Important: Metronidazole is now considered inferior to vancomycin and fidaxomicin for CDI. Failure rate ~19% vs 4% for vancomycin. IV may be used when oral is not tolerated, as it reaches bactericidal levels in inflamed colon.
| Patient | Dose |
|---|---|
| Child | 20 mg/kg/24 hr (max 1000 mg/24 hr) divided BID PO x 10-14 days |
| Adult | 250-500 mg TID-QID (with meals and at bedtime) PO x 10-14 days |
| Formulation | Frequency |
|---|---|
| 0.75% cream/gel | Apply BID |
| 1% cream/gel | Apply once daily |
For diarrhea
| Patient | Dose |
|---|---|
| Adult | 250 mg PO TID x 5 days |
| Child | 15-30 mg/kg/day divided Q8 hr x 5-10 days; max 250 mg/dose |
80-95% effective. Tinidazole (single dose) is preferred where available - it is superior to metronidazole. FDA has not formally approved metronidazole for Giardia but it is widely used.
| Patient | Dose |
|---|---|
| Adult | 500-750 mg PO TID x 10 days |
| Child | 35-50 mg/kg/24 hr divided Q8 hr x 10 days; max 750 mg/dose |
Must follow with a luminal agent (e.g. paromomycin or diloxanide furoate) to eradicate cysts.
| Severity | Adult Dose |
|---|---|
| Non-severe | 500 mg PO TID x 10-14 days |
| Cannot take oral | 500 mg IV Q8 hr (reaches bactericidal levels via inflamed mucosa) |
| Severe/fulminant (adjunct to vancomycin) | 500 mg IV Q8 hr |
Important caveat: Metronidazole is no longer first-line for CDI. Vancomycin (125 mg QID) and fidaxomicin are preferred. Metronidazole failure rate is ~19% vs ~4% for vancomycin. Reserve metronidazole for mild cases only when vancomycin/fidaxomicin are unavailable or as an adjunct in fulminant disease with IV route.
| Cause | Adult Dose | Duration |
|---|---|---|
| Giardia | 250 mg TID | 5 days |
| Amoebiasis | 500-750 mg TID | 10 days |
| C. difficile (non-severe) | 500 mg TID | 10-14 days |